Zapping a brain region may curb impulsivity in PSP

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 40 to 89 years * Patients with probable PSP according to the MDS-9 diagnostic criteria * BREF score \>10; * 18-FDG PET-MRI performed no more than 6 months prior to enrollment and showing: * Glucose hypometabolism defined as \> 2.5 SD compared to an atlas of healthy subjects and * No severe right frontal cortical atrophy according to F Pasquier's global cortical atrophy scale 53 * Concomitant treatments must have been stable for at least 4 weeks prior to enrollment and must remain stable throughout participation * Patient must have provided written informed consent * Patient must be enrolled in a social security program * Patient must be able to understand French and comply with the protocol * Women must use adequate contraceptive measures for the duration of the clinical trial (in accordance with CTFG recommendations) Exclusion Criteria: * Left-handed Patients; * Patients with severe apraxia that interferes with performance of the SST (at the investigator's discretion) * Known visual or hearing impairment that prevents performance of cognitive tests or the stop-signal test; * History of severe psychiatric or neurological disorders other than PSP; * Known significant brain injury(ies) (stroke, tumor, inflammation, post-traumatic, etc.), at the investigator's discretion * Atrophy of the right frontal lobe ≥3 on the F Pasquier Global Cortical Atrophy Scale 53 * History of epilepsy and seizures (or cerebral impairment with unexplained loss of consciousness), severe cardiac disorders, neurosurgical procedures, or severe or frequent headaches; * Presence of a cardiac, neural, drug-delivery, or cerebral stimulator * Presence of cerebral medical devices (such as vascular clips or electronically sensitive devices), intracerebral or intracochlear metal implants, * Patients with any electrically, magnetically, or mechanically activated implant * Patients suffering from a serious, life-threatening condition such as congestive heart failure, chronic obstructive pulmonary disease (COPD), or active neoplasia * Patients with skin conditions (dermatitis, psoriasis, or eczema) or lesions on the scalp or skull that preclude tDCS * Patients under legal guardianship or protective supervision * Pregnant or breastfeeding women * For patients in the ancillary study, contraindication to MRI: Presence of metallic foreign bodies